Search results for "Influenza"
Latest COVID-19 studies show need for repeat rapid testing, targeting of antiviral prescriptions
Viral load of SARS-CoV-2 doesn't peak until the fourth day of symptoms, one study found, while other research only saw an effect of nirmatrelvir/ritonavir on death and hospitalization among those who were moderately or severely immunocompromised, not in other high-risk groups.
https://immattersacp.org/weekly/archives/2023/10/03/2.htm
3 Oct 2023
Correcting myths about pneumococcus, flu, zoster vaccines
Vaccines have an undeserved bad reputation, so a Master of the College promotes their use and discusses common errors in administration..
https://immattersacp.org/archives/2009/06/vaccines.htm
1 Jun 2009
Modeling study finds RSV vaccines cost-effective for older U.S. adults
Vaccination programs using the monovalent adjuvanted or bivalent vaccine against respiratory syncytial virus (RSV) were projected to be potentially cost-effective at a price per dose of up to $127 or up to $118, respectively, over a first RSV season.
https://immattersacp.org/weekly/archives/2023/12/05/4.htm
5 Dec 2023
Busting COVID-19 vaccination myths
Misinformation and disinformation campaigns have contributed to the death toll of the COVID-19 pandemic. Internists can effectively counter this and encourage vaccinations.
https://immattersacp.org/archives/2021/11/busting-covid-19-vaccination-myths.htm
1 Nov 2021
ACP urges physicians to strongly recommend and offer flu shots to pregnant women following CDC report
As of early November 2017, almost two-thirds of pregnant women had not been vaccinated against the flu, according to the CDC.
https://immattersacp.org/weekly/archives/2018/01/30/2.htm
30 Jan 2018
Latest updates on ACP's priorities, initiatives
ACP Spotlight offers readers a look at ACP's current top priorities and initiatives, as well as highlights from our e-newsletter, ACP Internist Weekly.
https://immattersacp.org/archives/2019/03/latest-updates-on-acps-priorities-initiatives.htm
1 Mar 2019
Industry-funded studies may be more likely to recommend neuraminidase inhibitors
Industry-funded systematic reviews may be more likely to present favorable evidence about neuraminidase inhibitors and recommend their use than research without financial conflicts of interest, a study reported.
https://immattersacp.org/weekly/archives/2014/10/07/4.htm
7 Oct 2014
Warning on HCV treatments; more cancer drugs approved
This update also covers a warning that combination drugs can cause serious liver injury and approval of new drugs for metastatic non-small-cell lung cancer that has progressed after other treatments.
https://immattersacp.org/archives/2016/01/fda.htm
1 Jan 2016
Lessons learned from telemedicine
Although many internists may have felt inexperienced with telemedicine before the pandemic, they could well have been doing it all along.
https://immattersacp.org/archives/2020/10/lessons-learned-from-telemedicine.htm
1 Oct 2020
COVID-19 flu guidance, data on convalescent plasma, cardiac effects, and clot risk
Flu testing and treatment advice came from the NIH, convalescent plasma failed in a new trial, tocilizumab had mixed results, and remdesivir got full approval, among other COVID-19 news.
https://immattersacp.org/weekly/archives/2020/10/27/1.htm
27 Oct 2020